Cisplatin plus gemcitabine in platinum-refractory ovarian or primary peritoneal cancer: A Phase II Study of the Gynecologic Oncology Group-Reference-Cited by-同舟云学术

Cisplatin plus gemcitabine in platinum-refractory ovarian or primary peritoneal cancer: A Phase II Study of the Gynecologic Oncology Group

Published:2006-11 Issue:2 Volume:103 Page:446-450
ISSN:0090-8258
Container-title:Gynecologic Oncology
language:en
Short-container-title:Gynecologic Oncology

Author:

Brewer Cheryl A.,Blessing John A.,Nagourney Robert A.,Morgan Mark,Hanjani Parviz

Publisher

Elsevier BV

Subject

Obstetrics and Gynecology,Oncology

Reference23 articles.

1. The role of paclitaxel in the management of coelomic epithelial carcinoma of the ovary: a review with emphasis on the Gynecologic Oncology Group experience;Thigpen;Semin Oncol,1995

2. Phase II trial of paclitaxel in patients with progressive ovarian carcinoma after platinum-based chemotherapy: a Gynecologic Oncology Group study;Thigpen;J Clin Oncol,1994

3. Gemcitabine-induced pulmonary toxicity: case report and review of the literature;Gupta;Am J Clin Oncol,2002

4. Gemcitabine-associated hemolytic–uremic syndrome;Walter;Am J Kidney Dis,2002

5. Gemcitabine-induced erysipeloid skin lesions in a patient with malignant mesothelioma;Kuku;J Eur Acad Dermatol Venereol,2002

Cited by 53 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Platinum rechallenge treatment using gemcitabine plus carboplatin with or without bevacizumab for platinum-resistant ovarian cancer;International Journal of Clinical Oncology;2022-01-05

2. Neuropathological Effects of Chemotherapeutic Drugs;ACS Chemical Neuroscience;2021-08-09

3. Phase II trial of cisplatin, gemcitabine and pembrolizumab for platinum-resistant ovarian cancer;PLOS ONE;2021-06-03

4. The systemic treatment of recurrent ovarian cancer revisited;Annals of Oncology;2021-06

5. Comparison of Gemcitabine Plus Cisplatin vs. Docetaxel Plus Fluorouracil Plus Cisplatin Palliative Chemotherapy for Metastatic Nasopharyngeal Carcinoma;Frontiers in Oncology;2020-08-06